Company Share Purchase by CEO

RNS Number : 9885V

Genflow Biosciences PLC

15 August 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Company Share Purchase by CEO

Genflow Biosciences (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age,

announces that it was notified on 08 August 2022, that Eric Leire, a director of the Company, purchased the following Ordinary Shares:

PDMR / Person closely associated	Total Number of Ordinary Shares Purchased	Weighted Average Price per Ordinary Share	Resultant Shareholding	Percentage Of The Total Voting Rights of the Company
Eric Leire	106,000	0.028	120,414,999	41.17

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link:

https://genflowbio.com/investors/news-releases/

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

Genflow Biosciences
Dr Eric Leire Chief Executive	via Tancredi +44 203 434 2330
Clear Capital
Corporate Broker Jonathan Critchley Keith Swann	+44 203 869 6086 +44 203 897 0981
Tancredi Intelligent Communication Media Relations
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio	+44 7957 549 906 +44 7449 226 720 +44 7838 029 970 [email protected]

About Genflow Biosciences

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researchs, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPURPRUPPUAA